Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Energy Systems Fatigue is one of the most commonly reported side effects of semaglutide
Consumers Taking GLP-1s for Weight Loss, Current or Discontinued, Drive Lasting Changes in Retail, Per New Acosta Group Study News provided by Acosta Group Apr 14, 2025, 12:05 ET 76% of those who discontinued GLP-1s are eating the same amount or less and many report retaining healthy habits JACKSONVILLE, Fla., April 14, 2025 /PRNewswire/ -- In advance of the National Association of Chain Drug Stores (NACDS) Annual Meeting, Acosta Group is sharing the results of its recent proprietary GLP-1 Shopper Community study, focusing on consumers using the medications specifically to support weight loss
doi: 10.1038/nm.3145.[PMC free article] [PubMed] [CrossRef] Kolker S, Christensen E, Leonard JV, et al
The rapid weight loss on Wegovy is driven by the caloric deficit induced by the medication
This aligns with emerging research suggesting that GLP-1 receptor agonists may modulate reward pathways in the brain beyond just food-related signals
At lower (micro) doses, compounded tirzepatide may also be beneficial for patients who: Have side effects at higher doses Would like to reduce cardiovascular disease risk Would like to reduce inflammation Would like to improve gastrointestinal conditions such as inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) Would like to protect against Alzheimers or Parkinsons disease Would like to reduce the use of alcohol or tobacco Important Safety Information for Compounded Tirzepatide Injection Warning: Risk of Thyroid C-Cell Tumors In studies with mice and rats, tirzepatide caused thyroid tumors, including thyroid cancer
US$ 28.54
US$ 28.42
US$ 26.19
US$ 20.25
US$ 20.86
US$ 20.70
